More in the News
Senate Finance Committee Urges PBMs To Make Big Changes
Senators and witnesses at today's Senate Finance Committee on PBMs took aim at PBMs for their role in what they say keeps drug prices high for consumers and for the Medicare program.
Pharmacy orgs commend Senate intro of ‘Drug Pricing Transparency in Medicaid Act’
The National Association of Chain Drug Stores and the National Community Pharmacists Association are lauding the introduction of S. 1038, the Drug Pricing Transparency in Medicaid Act, introduced by U.S. Sens. Peter Welch (D-Vt.) and Roger Marshall (R-Kan.).
Some seniors could start paying less for certain drugs whose prices rose faster than inflation
Starting next month, some Medicare beneficiaries will pay less out of pocket for 27 prescription drugs whose prices rose faster than inflation late last year, the Department of Health and Human Services said Wednesday.
Congress Investigates How Pharma Middlemen Affect Drug Prices
House Republicans have launched an investigation into the companies that manage drug benefits, dialing up the scrutiny of the middlemen who play an important role in how much medicines cost.
The administration's next crack at lower drug prices
The Biden administration unveiled three drug payment programs Tuesday aimed at helping reduce patients' out-of-pocket costs, including one that would potentially lower Medicare payments for promising treatments approved by the FDA before clinical trials are complete.
Your Money or Your Life: Patient on $50,000-a-Week Cancer Drug Fears Leaving Behind Huge Medical Debt
After several rounds of treatment for a rare eye cancer — weekly drug infusions that could cost nearly $50,000 each — Paul Davis learned Medicare had abruptly stopped paying the bills.
Watch: Blockbuster drug Humira has new competition. Here’s why that matters
Humira has been the world's best selling medicine since it arrived on the market in 2002. Now, it is finally getting competition.
US Government to Start Imposing Inflation Penalties on Drugmakers in 2025
The U.S. government will begin imposing penalties in 2025 on drug companies that charge its Medicare program prices that rise faster than inflation, the Centers for Medicare & Medicaid Services said on Thursday.
Judiciary Committee again advances drug patent reform bill package
The Senate Judiciary Committee on Thursday advanced five bipartisan bills that aim to boost generic and biosimilar competition in the pharmaceutical marketplace by voice vote.
Decisions by CVS and Optum Panicked Thousands of Their Sickest Patients
The fear started when a few patients saw their nurses and dietitians posting job searches on LinkedIn. Word spread to Facebook groups, and patients started calling Coram CVS, a major U.S. supplier of the compounded IV nutrients on which they rely for survival.